Syndax Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
Syndax Pharmaceuticals, Inc. (SNDX) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $0 as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $119.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $452.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $525.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 |
| 2026-03-31 | $119.00K 10-Q · filed 2026-04-30 |
| 2025-12-31 | $452.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $525.00K 10-Q · filed 2025-11-03 |
| 2025-06-30 | $305.00K 10-Q · filed 2025-08-04 |
| 2025-03-31 | $526.00K 10-Q · filed 2025-05-05 |
| 2024-12-31 | $219.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $371.00K 10-Q · filed 2024-11-05 |
| 2023-12-31 | $257.00K 10-K · filed 2025-03-03 |
| 2023-03-31 | $36.00K 10-Q · filed 2023-05-08 |
| 2022-06-30 | $1.00K 10-Q · filed 2022-08-08 |
| 2021-12-31 | $70.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $14.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $24.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $23.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $15.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $55.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $135.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $86.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $5.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $25.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $58.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $8.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $3.00K 10-Q · filed 2018-11-05 |
| 2018-06-30 | $5.00K 10-Q · filed 2018-08-08 |
| 2017-09-30 | $45.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $74.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $21.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $67.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $120.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $204.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $229.00K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $48.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |